Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HG146 Alone or in Combination With PD-(L)1 Inhibitor in Advanced Solid Tumors or Lymphoma
NCT04977167Phase 1Completed
- Sponsor
- HitGen
- Start
- Sep 2021
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of HG146 in solid tumor and lymphoma (4 cohorts), sponsored by HitGen. Primary endpoints: Dose-Limiting Toxicities, Serious Adverse Events and Adverse Events up to 2 years and 1 more. Started Sep 2021; status: completed.
02
Drugs
HG146
03
Conditions
solid tumorlymphoma
Beyond the preview
Go deeper on NCT04977167.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04977167.